# PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

> **NCT06133517** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Fundación para el Progreso de la Oncología en Cantabria** · enrollment: 70 (estimated)

## Conditions studied

- Urothelial Bladder Carcinoma

## Interventions

- **DRUG:** Sacituzumab govitecan
- **DRUG:** Zimberelimab
- **DRUG:** Domvanalimab

## Key facts

- **NCT ID:** NCT06133517
- **Lead sponsor:** Fundación para el Progreso de la Oncología en Cantabria
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-20
- **Primary completion:** 2030-01
- **Final completion:** 2030-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06133517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06133517, "PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06133517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*